Optomed Q2: Revenue growth, expanding margins
Redeye maintains at this point Optomed's valuation at EUR 13 per share after the strong Q2 report. We expect the company to continue delivering solid results this year, followed by stronger growth in 2022, both of camera and of software revenues, and further improving gross margins.
Sign up for free to continue
Already a member?
Disclosures and disclaimers
Premium Plan required to unlock